Bryce Point Capital’s Moderna MRNA Stock Holding History

Bryce Point Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-28,268	Closed	-$944K	–	234
2025 Q1	$944K	Buy	+28,268	New	+$1M	0.71%	40

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bryce Point Capital's MRNA Position: Q2 2025 in Review

Bryce Point Capital sold out of Moderna (MRNA) in Q2 2025, closing a stake of 28,268 shares — an estimated $944K sold.

Bryce Point Capital first reported a position in MRNA in Q1 2025 and held it in 1 quarter. The position peaked at $944K in Q1 2025. 674 funds tracked by Wall St. Rank hold MRNA as of Q2 2025.

Bryce Point Capital reported no remaining Moderna position as of Q2 2025 after selling out during the quarter.
Bryce Point Capital sold 28,268 Moderna shares in Q2 2025, an estimated $944K.
Bryce Point Capital first reported a position in Moderna in Q1 2025 and held it in 1 quarter.
Bryce Point Capital's Moderna position peaked at $944K in Q1 2025.
674 funds tracked by Wall St. Rank held Moderna as of Q2 2025.

Based on Bryce Point Capital's 13F filing for Q2 2025, filed 5 Aug 2025.